Claim: GSK builds oncology pipeline as drug shown to help myeloma patients.
Verdict: SUPPORTS

Retrieved passages:
title: Reolysin
text: Oncolytics announced that cancer charity Myeloma UK launched MUK "eleven", a phase 1b trial studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Imnovid® (pomalidomide) or Revlimid® (lenalidomide), as a rescue treatment in relapsing myeloma patients. The first patient was treated in September 2017. Oncolytics is conducting two phase 2 clinical trials studying REOLYSIN in pancreatic cancer: in collaboration with the University of Texas, Oncolytics is studying REOLYSIN in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer, and in collaboration with the NCI, Oncolytics is studying REOLYSIN in combination with carboplatin and paclitaxel as a first line

title: Oncolytics Biotech
text: phase 1b trial. The trial will assess the safety and dose-limiting toxicity of REOLYSIN in combination with pembrolizumab (KEYTRUDA®) and chemotherapy in patients with advanced or metastatic pancreatic adenocarcinoma who have failed, or did not tolerate, first line treatment. In March 16, 2017 Oncolytics announced that cancer charity Myeloma UK launched MUK "eleven", a phase 1b trial studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Imnovid® (pomalidomide) or Revlimid® (lenalidomide), as a rescue treatment in relapsing myeloma patients. The first patient was treated in September 2017. Oncolytics is conducting two phase 2 clinical trials studying REOLYSIN in pancreatic

title: William A. Haseltine
text: that has proved to be an effective treatment for multiple myeloma and other cancers. Haseltine and a colleague also founded LeukoSite Inc. to develop drugs to treat autoimmune diseases. LeukoSite, also initially funded by Healthcare Ventures, acquired ProScript which in turn was acquired by Millenium Pharmaceuticals, the company that successfully brought Velcade to market. Millennium was acquired in 2008 by Takeda Pharmaceutical Company. Today Velcade is an important drug in the treatment of multiple myeloma. Knowledge of the importance of dendritic cells in HIV infection provided the insight that led to the formation of a company that pioneered immune cell

title: Multiple myeloma
text: patients with "relapsed disease", bortezomib is a recent addition to the therapeutic arsenal, especially as second line therapy, since 2005. Bortezomib is a proteasome inhibitor. Also, lenalidomide (Revlimid), a less toxic thalidomide analog, is showing promise for treating myeloma. The newly approved thalidomide derivative pomalidomide (Pomalyst in the U.S.) may be used for relapsed and refractory multiple myeloma. In the 21st century, more patients have survived longer, as a result of stem cell transplant (with their own or a donor's) and treatments combining bortezomib (Velcade), dexamethasone and melphalan or cyclophosphamide. This seems to maintain the monoclonal peak at a reasonable

title: Multiple myeloma
text: benefit from a bortezomib based maintenance regimen. The natural history of myeloma is of relapse following treatment. This may be attributed to tumor heterogeneity. Depending on the patient's condition, the prior treatment modalities used and the duration of remission, options for relapsed disease include re-treatment with the original agent, use of other agents (such as melphalan, cyclophosphamide, thalidomide or dexamethasone, alone or in combination), and a second autologous stem cell transplant. Later in the course of the disease, "treatment resistance" occurs. This may be a reversible effect, and some new treatment modalities may re-sensitize the tumor to standard therapy. For

title: GenSpera
text: G-202, is currently in a Phase II clinical trial for patients with hepatocellular carcinoma (HCC) whose disease has failed to improve on standard therapy for this indication. G-202 is also being evaluated in a Phase II clinical trial in glioblastoma patients with recurrent disease after surgery and/or radiation treatment of the primary tumor. G-202 targets the enzyme PSMA, found on the walls of blood vessels that feed most cancerous tumors, destroying the tumor blood supply. In contrast with anti-angiogenic agents, G-202 destroys existing as well as new cancer blood vessels. G-202 received Orphan Drug Designation from U.S. Food and Drug

title: Bortezomib
text: with low-dose intravenous immunoglobulins, plasmapheresis, and rituximab. Bortezomib Bortezomib (BAN, INN and USAN; marketed as Velcade by Takeda Oncology; Chemobort by Cytogen and Bortecad by Cadila Healthcare) is an anti-cancer drug and the first therapeutic proteasome inhibitor to be used in humans. Proteasomes are cellular complexes that break down proteins. In some cancers, the proteins that normally kill cancer cells are broken down too quickly. Bortezomib interrupts this process and lets those proteins kill the cancer cells. It is approved in the U.S. and Europe for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses

title: Daratumumab
text: 1/2 clinical trial in relapsed multiple myeloma patients. Updated trial results presented in December 2012 indicate daratumumab is continuing to show promising single-agent anti-myeloma activity. A 2015 study compared monotherapy 8 and 16 mg/kg at monthly to weekly intervals. Daratumumab was given priority review status by the FDA for multiple myeloma as a combination therapy (second line). Daratumumab Daratumumab (trade name Darzalex) is an anti-cancer drug. It binds to CD38, which multiple myeloma cells overexpress. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which

title: Genmab
text: July 2010. GSK has taken responsibility for developing ofatumumab in autoimmune indications while continuing to jointly develop ofatumumab with Genmab in oncology indications. Genmab received an up front payment of GBP 90 million from GSK in relation to the amendment and the Company's future funding commitment is capped at GBP 145 million. Further milestones due to Genmab under the oncology development program will be reduced by 50%. GSK is now solely responsible for funding development in autoimmune indications and Genmab will forgo development milestones for autoimmune indications and the first two sales milestones. In addition, Genmab has collaborations with Roche

title: Filanesib
text: European Hematology Association in Stockholm. On October 31, 2013, it was reported that the company which developed the drug, Array BioPharma (based in Boulder, Colorado), was planning on launching a phase III clinical trial of the drug to treat multiple myeloma. The study began in mid-2014, and paired filanesib with the proteasome inhibitor carfilzomib in several hundred patients. The study's primary endpoint was progression-free survival (i.e. the time until the cancer recurs). A previous trial had reported that 37% of patients receiving filanesib in conjunction with carfilzomib showed lower levels of paraprotein, also known as "M protein", whereas only 16%

title: Bortezomib
text: Bortezomib Bortezomib (BAN, INN and USAN; marketed as Velcade by Takeda Oncology; Chemobort by Cytogen and Bortecad by Cadila Healthcare) is an anti-cancer drug and the first therapeutic proteasome inhibitor to be used in humans. Proteasomes are cellular complexes that break down proteins. In some cancers, the proteins that normally kill cancer cells are broken down too quickly. Bortezomib interrupts this process and lets those proteins kill the cancer cells. It is approved in the U.S. and Europe for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise

title: Millennium Pharmaceuticals
text: when Millennium licensed the exclusive U.S. commercialization and development rights of Integrilin to Schering-Plough. In May 2003 Velcade was launched for the treatment of relapsed and refractory multiple myeloma – a cancer of the blood. At the time, the U.S. Food and Drug Administration (FDA) granted approval for the treatment of multiple myeloma for patients who had not responded to at least two other therapies for the disease. Velcade — the first FDA-approved proteasome inhibitor — reached the market in record time and represented the first treatment in more than a decade to be approved for patients with multiple myeloma.

title: Onyx Pharmaceuticals
text: Stivarga), is currently being studied as a potential treatment option in multiple tumor types. On 27 September 2012, the FDA approved regorafenib for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild-type, an anti-EGFR therapy. On February 25, 2013, the FDA approved regorafenib in a second indication to treat patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is a compound developed by Bayer. The most common adverse

title: Chronic myelogenous leukemia
text: of leukemogenic effects and hence the relative lack of potential for secondary hematologic malignancies to result from treatment. IRIS, an international study that compared interferon/cytarabine combination and the first of these new drugs imatinib, with long-term follow up, demonstrated the clear superiority of tyrosine-kinase-targeted inhibition over existing treatments. The first of this new class of drugs was imatinib mesylate (marketed as Gleevec or Glivec), approved by the U.S. Food and Drug Administration (FDA) in 2001. Imatinib was found to inhibit the progression of CML in the majority of patients (65–75%) sufficiently to achieve regrowth of their normal bone marrow stem

title: Bortezomib
text: refractory or rapidly advancing disease. Bortezomib was originally synthesized in 1995 at Myogenics. The drug (PS-341) was tested in a small Phase I clinical trial on patients with multiple myeloma. It was brought to further clinical trials by Millennium Pharmaceuticals in October 1999. In May 2003, seven years after the initial synthesis, bortezomib (marketed as Velcade by Millennium Pharmaceuticals Inc.) was approved in the United States by the Food and Drug Administration (FDA) for use in multiple myeloma, based on the results from the SUMMIT Phase II trial. Bortezomib is approved for initial treatment of patients with multiple myeloma by

title: Multiple myeloma
text: in asymptomatic ("smoldering") myeloma, treatment is typically deferred, or restricted to clinical trials. In addition to direct treatment of the plasma cell proliferation, bisphosphonates (e.g., pamidronate or zoledronic acid) are routinely administered to prevent fractures; they have also been observed to have a direct anti-tumor effect even in patients without known skeletal disease. If needed, red blood cell transfusions or erythropoietin can be used for management of anemia. Initial treatment of multiple myeloma depends on the patient’s age and other illnesses present. The preferred treatment for those under the age of 65 is high-dose chemotherapy, commonly with bortezomib based regimens,

title: Genmab
text: drug that could be used for treatment in CD20 positive B-cell chronic lymphocytic leukemia, follicular non-Hodgkin’s lymphoma, rheumatoid arthritis and other indications. The agreement gave Genmab a license fee of DKK 582 million and GSK bought 4,471,202 shares of Genmab for 2,033 million. The potential value of this agreement could be 12.0 billion DKK if all milestones are reached and commercial success is reached in the fields of cancer, autoimmune, and inflammatory disease. Until 2008, Genmab will bear the entire development cost, after which the costs will be shared equally between the two. Genmab and GSK amended the agreement in

title: Craig M. Crews
text: his lab, which ultimately became carfilzomib. Marketed under the trade name Kyprolis, carfilzomib was approved by the FDA on June 20, 2012 for use in patients with multiple myeloma who have received at least two prior therapies and have demonstrated disease progression on or within 60 days of completion of the last therapy. Based on successful Phase II trials of carfilzomib, Onyx Pharmaceuticals acquired Proteolix in 2009 and was itself acquired by Amgen in 2013 for $10.4 billion. In 2013, Crews founded New Haven-based Arvinas, LLC, which uses the PROTAC protein degradation technology from his lab to develop drugs to

title: Paul-Peter Tak
text: research into medicines for patients - led to Tak being appointed GSK's Senior Vice President of their ImmunoInflammation Therapy Area in 2011; this unit searches for the most promising solutions in rheumatology, gastroenterology and dermatology. He oversaw the creation of a portfolio of potential medicines for immune-mediated inflammatory diseases and pain, including anti-OSM antibody, anti-LAG3 antibody, RIP1 kinase inhibitor, ESM-BET inhibitor, anti-GM-CSF antibody, anti-CCL17 antibody and Benlysta sc. Later, he also led the Oncology and Infectious Disease Therapy Area Units. Tak became a member of GSK’s R&D Leadership in 2011 but has also retained an interest in several other companies

title: Pomalidomide
text: and myelofibrosis reported 'promising results'. Phase III results showed significant extension of progression-free survival, and overall survival (median 11.9 months vs. 7.8 months; "p" = 0.0002) in patients taking pomalidomide and dexamethasone vs. dexamethasone alone. Pomalidomide directly inhibits angiogenesis and myeloma cell growth. This dual effect is central to its activity in myeloma, rather than other pathways such as TNF alpha inhibition, since potent TNF inhibitors including rolipram and pentoxifylline do not inhibit myeloma cell growth or angiogenesis. Upregulation of interferon gamma, IL-2 and IL-10 as well as downregulation of IL-6 have been reported for pomalidomide. These changes may contribute